USPTO experts discuss new findings and growth potential across AI and emerging technologies.
Cross-collaboration and changes to acquisition are key as priorities shift.
The group will consolidate data and resources to research and develop COVID-19 pharmaceutical solutions.
Research and AI programs are approaching a standstill while funding for the U.S. federal government has lapsed.
The race for global leadership in innovation depends on investment and international collaboration.